• Purity

  >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie? Blue Staining.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated mouse T cells. The ED    ₅₀ for this effect is 0.15-0.75 μg/mL.

• Source

  Mouse myeloma cell line, NS0-derived

  Mouse PD-L1 (Phe19-Thr238) Accession # Q9EP73	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Phe19

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  51.3 kDa (monomer)

• SDS-PAGE

  75-85 kDa, reducing conditions

Data Images

Background: PD-L1/B7-H1

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature mouse B7-H1 consists of a 221 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain (2). Within the ECD, mouse B7-H1 shares 73% and 86% aa sequence identity with human and rat B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (2-5), keratinocytes (6, 7), enothelial and intestinal epithelial cells (6, 8), as well as a variety of carcinomas and melanoma (9, 10). B7-H1 binds to T cell B7-1/CD80 and PD-1 (5, 6, 10-13). It suppresses T cell activation and proliferation (3, 6, 12, 14) and induces the apoptosis of activated T cells (9). It plays a role in the development of immune tolerance by promoting T cell anergy (5, 12) and enhancing regulatory T cell development (14). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (3, 8) and inhibits the development of Th17 cells (14). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (4, 7, 10, 13).

• References:

1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.

2. Tamura, H. et al. (2001) Blood 97:1809.

3. Chen, L. et al. (2007) J. Immunol. 178:6634.

4. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.

5. Tsushima, F. et al. (2007) Blood 110:180.

6. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.

7. Cao, Y. et al. (2010) Cancer Res. 71:1235.

8. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.

9. Dong, H. et al. (2002) Nat. Med. 8:793.

10. Azuma, T. et al. (2008) Blood 111:3635.

11. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.

12. Park, J.-J. et al. (2010) Blood 116:1291.

13. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.

14. Herold, M. et al. (2015) J. Immunol. 195:3584.

• Long Name:

  B7 Homolog 1

• Entrez Gene IDs:

  29126 (Human); 60533 (Mouse); 499342 (Rat); 484186 (Canine); 102145573 (Cynomolgus Monkey)

• Alternate Names:

  B7-H; B7H1; B7-H1; B7H1PDCD1L1; CD274 antigenMGC142294; CD274 molecule; CD274; PDCD1L1; PDCD1LG1; PDCD1LG1MGC142296; PDL1; PD-L1; PD-L1B7 homolog 1; PDL1PDCD1 ligand 1; programmed cell death 1 ligand 1; Programmed death ligand 1